Conceivable Life Sciences

Conceivable Life Sciences is developing AURA, an integrated, automated platform designed to perform all key functions of an IVF laboratory, from sperm processing to embryo vitrification. Founded in 2021, the company addresses a massive unmet need in fertility care, where an estimated 95% of those needing IVF cannot access it due to high costs and manual, unscalable processes. With a $50M Series A raise and an initial clinical validation site operational in Mexico City, Conceivable is positioning its automated lab as a scalable solution for IVF clinics, aiming to transform a largely artisanal practice into a standardized, high-throughput service. The long-term vision is to make IVF a more affordable and accessible therapy for millions worldwide.

AURA (Automated IVF Lab): An integrated system of six robotic workstations that uses AI, machine vision, advanced optics, and precision robotics to fully automate all key IVF laboratory procedures, including ICSI, incubation, and vitrification, with native digital specimen traceability.

The competitive landscape for full IVF lab automation is nascent but developing. Conceivable appears to be a first-mover with its integrated AURA system. Competition includes companies developing point solutions for specific IVF steps (e.g., automated ICSI devices) and larger medical robotics or life science tools firms that could enter the space. The primary competition, however, remains the entrenched manual practice of IVF itself, which the company must displace by demonstrating superior economics and outcomes.